A six-month course of treatment with mycophenolate mofetil (MMF) is as effective as conventional therapies for treating membranous nephropathy (MN) and focal segmental glomerulosclerosis (FSGS), according to a pilot study conducted in India.

FOCAL SEGMENTAL glomerulosclerosis (FSGS) is not a single disease but a histologic pattern of renal damage that initially affects the glomerulus and its tubulointerstitium (Nat Clin Pract Nephrol. 2005;1:44-54). FSGS is a leading cause of nephrotic syndrome worldwide and may be found in up to 35% of nephrotic individuals.

Five-year data gathered by the Paulista Registry of Glomerulopathies in São Paulo, Brazil, shows that focal and segmental glomerulosclerosis is the most common primary glomerular disease, followed by membranous nephropathy and IgA nephropathy.